EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors

Emma Titmuss iD, Irene S Yu, Erin D Pleasance iD, Laura M Williamson, Karen Mungall, Andrew J Mungall iD, Daniel J Renouf, Richard Moore, Steven J M Jones iD, Marco A Marra iD, Janessa J Laskin, Kerry J Savage

Current Oncology · 2024

DOI: 10.3390/curroncol31040140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Emma Titmuss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genome British Columbia, Genome Canada, Canada Foundation for Innovation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitors (ICIs) are increasingly used in the treatment of many tumor types, and durable responses can be observed in select populations. However, patients may exhibit significant immune-related adverse events (irAEs) that may lead to morbidity. There is limited information on whether the presence of specific germline mutations may highlight those at elevated risk of irAEs. We evaluated 117 patients with metastatic solid tumors or hematologic malignancies who underwent genomic analysis through the ongoing Personalized OncoGenomics (POG) program at BC Cancer and received an ICI during their treatment history. Charts were reviewed for irAEs. Whole genome sequencing of a fresh biopsy and matched normal specimens (blood) was performed at the time of POG enrollment. Notably, we found that MHC class I alleles in the HLA-B27 family, which have been previously associated with autoimmune conditions, were associated with grade 3 hepatitis and pneumonitis (q = 0.007) in patients treated with combination PD-1/PD-L1 and CTLA-4 inhibitors, and PD-1 inhibitors in combination with IDO-1 inhibitors. These data highlight that some patients may have a genetic predisposition to developing irAEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsNeoplasmsHumansMaleFemaleMiddle AgedAgedGerm-Line MutationAdultAged, 80 and over

Stichwörter der Autor:innen

cancergenomicsimmune checkpoint inhibitorsimmune-related adverse eventsimmunotherapy

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada.
  • Department of Medical Oncology, BC Cancer, Surrey, BC V3V 1Z2, Canada.
  • Canada's Michael Smith Genome Sciences Centre, Vancouver, BC V5Z 4S6, Canada.
  • Pancreas Centre BC, Vancouver, BC V5Z 1G1, Canada.
  • Michael Smith Laboratories, University of British Columbia, Vancouver, BC V6T 1Z4, Canada.
  • Department of Medical Genetics, University of British Columbia, Vancouver, BC V6T 2A1, Canada.

ORCID-Profile: Emma Titmuss, Erin D Pleasance, Andrew J Mungall, Steven J M Jones, Marco A Marra

Förderung

  • Genome British Columbia
  • Genome Canada
  • Canada Foundation for Innovation
  • British Columbia Cancer Foundation
  • Genome Canada and Genome BC

Zitieren

APA

Titmuss, E., Yu, I. S., Pleasance, E. D., Williamson, L. M., Mungall, K., Mungall, A. J., Renouf, D. J., Moore, R., Jones, S. J. M., Marra, M. A., Laskin, J. J., & Savage, K. J. (2024). Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. https://doi.org/10.3390/curroncol31040140

Vancouver

Titmuss E, Yu IS, Pleasance ED, Williamson LM, Mungall K, Mungall AJ, et al. Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors. Current Oncology. 2024. doi:10.3390/curroncol31040140

BibTeX
@article{Titmuss2024,
  author = {Titmuss, Emma and Yu, Irene S and Pleasance, Erin D and Williamson, Laura M and Mungall, Karen and Mungall, Andrew J and Renouf, Daniel J and Moore, Richard and Jones, Steven J M and Marra, Marco A and Laskin, Janessa J and Savage, Kerry J},
  title = {Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31040140}
}
Kostenlos starten →